PetIQ, Inc. (PETQ) Income Statement Analysis

See more : DUROPLY INDUSTRIES LIMITED (DUROPLY.BO) Income Statement Analysis – Financial Results

Complete financial analysis of PetIQ, Inc. (PETQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PetIQ, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.

You may be interested

Spice Private Equity AG (SPCE.SW) Income Statement Analysis – Financial Results
Attica Publications S.A. (ATEK.AT) Income Statement Analysis – Financial Results
Y’s Table Corporation (2798.T) Income Statement Analysis – Financial Results
E-Monee.com, Inc (EMNC) Income Statement Analysis – Financial Results
Zhejiang Jinghua Laser Technology Co.,Ltd (603607.SS) Income Statement Analysis – Financial Results

PetIQ, Inc. (PETQ)

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Website: https://petiq.com

About PetIQ, Inc.

PetIQ, Inc. operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which include flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as distributes third-party branded medications. It also provides OTC medications and supplies primarily within the flea and tick control, and behavior management categories of the health and wellness industry in various forms, such as spot on (topical) treatments, chewables, oral tablets, and collars. In addition, the company offers health and wellness products that include dental treats and nutritional supplements, which comprise hip and joint, vitamins, and skin and coat products. The company provides its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PetLock, Heart Shield Plus, TruProfen, Betsy Farms, PetAction, Minties, Vera, and Delightibles brands. In addition, the company offers a suite of services at 2,900 community clinics and wellness centers hosted at pet retailers across 42 states, including diagnostic tests, vaccinations, prescription medications, microchipping, and wellness checks. It operates through approximately 60,000 points of distribution across veterinarian, retail, and e-commerce channels. The company was founded in 2010 and is headquartered in Eagle, Idaho.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue	1.10B	921.51M	932.53M	780.05M	709.43M	528.61M	266.69M	200.16M	205.69M	161.49M
Cost of Revenue	849.22M	711.85M	746.14M	644.86M	602.05M	445.33M	215.49M	167.62M	166.53M	139.69M
Gross Profit	252.74M	209.66M	186.39M	135.19M	107.38M	83.29M	51.19M	32.55M	39.16M	21.80M
Gross Profit Ratio	22.94%	22.75%	19.99%	17.33%	15.14%	15.76%	19.20%	16.26%	19.04%	13.50%
Research & Development	1.10M	2.10M	8.00M	2.30M	1.30M	203.00K	514.00K	310.00K	380.00K	1.14M
General & Administrative	146.03M	162.46M	170.52M	138.38M	103.20M	72.26M	37.91M	31.85M	35.59M	23.42M
Selling & Marketing	45.60M	20.10M	16.20M	10.10M	4.50M	2.90M	2.20M	1.20M	6.08M	5.49M
SG&A	191.63M	182.56M	170.52M	138.38M	103.20M	72.26M	37.91M	31.85M	35.59M	28.91M
Other Expenses	-160.00K	130.00K	1.92M	571.00K	172.00K	-345.00K	201.00K	666.00K	0.00	0.00
Operating Expenses	192.73M	182.56M	170.52M	138.38M	103.20M	72.26M	37.91M	31.85M	35.59M	31.81M
Cost & Expenses	1.04B	894.41M	916.66M	783.24M	705.25M	517.59M	253.40M	199.46M	202.12M	171.50M
Interest Income	0.00	27.40M	24.70M	22.81M	400.00K	0.00	0.00	0.00	0.00	980.00K
Interest Expense	34.55M	27.37M	24.70M	26.30M	14.50M	8.02M	1.56M	3.06M	3.55M	0.00
Depreciation & Amortization	44.57M	32.62M	36.67M	24.88M	15.14M	11.90M	3.40M	2.98M	3.14M	2.30M
EBITDA	81.49M	12.59M	48.85M	22.38M	12.42M	19.62M	16.83M	2.65M	4.77M	-5.96M
EBITDA Ratio	9.49%	6.80%	6.12%	3.64%	2.94%	4.38%	6.41%	2.72%	3.26%	-3.69%
Operating Income	60.02M	27.23M	15.87M	-2.62M	4.36M	7.75M	13.29M	702.00K	3.57M	-8.25M
Operating Income Ratio	5.45%	2.96%	1.70%	-0.34%	0.61%	1.47%	4.98%	0.35%	1.74%	-5.11%
Total Other Income/Expenses	-34.71M	-27.24M	-28.39M	-22.13M	-14.47M	-8.32M	-1.50M	-4.10M	-4.92M	-870.00K
Income Before Tax	2.37M	-47.41M	-12.51M	-28.81M	-17.61M	-574.00K	11.79M	-3.40M	-1.35M	-10.99M
Income Before Tax Ratio	0.21%	-5.14%	-1.34%	-3.69%	-2.48%	-0.11%	4.42%	-1.70%	-0.66%	-6.81%
Income Tax Expense	-173.00K	1.21M	3.87M	52.22M	-3.31M	-661.00K	3.97M	3.00K	-1.35M	-6.00K
Net Income	2.13M	-48.62M	-16.38M	-81.02M	-14.30M	-782.00K	-3.49M	-3.40M	-1.35M	-10.99M
Net Income Ratio	0.19%	-5.28%	-1.76%	-10.39%	-2.02%	-0.15%	-1.31%	-1.70%	-0.66%	-6.80%
EPS	0.07	-1.67	-0.58	-3.29	-0.63	-0.05	-0.26	-0.28	-0.11	-0.89
EPS Diluted	0.07	-1.67	-0.58	-3.29	-0.63	-0.05	-0.26	-0.28	-0.11	-0.89
Weighted Avg Shares Out	29.14M	29.16M	28.24M	24.63M	22.65M	17.22M	13.22M	12.29M	12.29M	12.29M
Weighted Avg Shares Out (Dil)	29.53M	29.16M	28.24M	24.63M	22.65M	17.22M	13.22M	12.29M	12.29M	12.29M

PetIQ, Inc. Announces Successful Completion of Acquisition by Bansk Group

October 25, 2024globenewswire.com

EAGLE, Idaho and NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication, health and wellness company, today announced the successful completion of its acquisition by Bansk Group (“Bansk”), a...

PetIQ, Inc. Announces Results of Special Meeting of Stockholders

October 22, 2024globenewswire.com

Reports Merger Agreement with Bansk Group Approved by Stockholders and Anticipates a Closing Date of October 25, 2024 Reports Merger Agreement with Bansk Group Approved by Stockholders and Anticipates a Closing Date of October 25, 2024

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Mergers and Upcoming Votes of PETQ and FBMS

October 9, 2024accesswire.com

NEW YORK, NY / ACCESSWIRE / October 9, 2024 / Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services...

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers and Imminent Votes of PETQ and FBMS

October 8, 2024accesswire.com

NEW YORK, NY / ACCESSWIRE / October 8, 2024 / Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services...

STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Mergers and Imminent Votes of PETQ and FBMS

October 7, 2024accesswire.com

NEW YORK, NY / ACCESSWIRE / October 7, 2024 / Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services...

PetIQ, Inc. (PETQ) Hits Fresh High: Is There Still Room to Run?

October 3, 2024zacks.com

PetIQ (PETQ) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Fast-paced Momentum Stock PetIQ (PETQ) Is Still Trading at a Bargain

September 20, 2024zacks.com

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, PetIQ (PETQ) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at...

PetIQ (PETQ) Upgraded to Strong Buy: What Does It Mean for the Stock?

September 13, 2024zacks.com

PetIQ (PETQ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Should Value Investors Buy PetIQ (PETQ) Stock?

September 12, 2024zacks.com

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong...